

14 Oct 2020 |

APAC Podcast: China Vaccines, NASH In Korea, Digital Shifts, India Q2 And Japan Deals

by Ian Haydock

Join the Asia content team for a wide-ranging overview and analysis of developments and trends in the region, including coronavirus vaccines in China, Korean developments in NASH, digital health shifts, Indian corporate performance and Japanese deal trends.

The Asia-based content team for *Scrip* and the *Pink Sheet* dissect some of the major events shaping the regional pharma industry over the past few months, including but also beyond the coronavirus pandemic.

Join Brian Yang in Beijing, Jung Won Shin in Seoul, Anju Ghangurde and Vibha Ravi in Mumbai and Ian Haydock in Tokyo for a top-line overview of key developments.

[Click here to explore this interactive content online](#) 

Coronavirus Vaccine Developments In China

China's rapid progress with the development of vaccine candidates, which it is intending to supply internationally, is being watched closely across the world. Brian looks at the current state of play, the state of the pandemic in the country and how things will move forward.

Korea Emerging As A NASH Contender (Starts 8:54)

Jung Won examines how South Korean companies have entered the global stage for the increasingly competitive non-alcoholic steatohepatitis (NASH) area, through the development of original drugs and plans to both develop these domestically or partner globally.

Digital Developments (Starts 13:19)

In this section, Anju takes an overview on the developments in the broad digital space, including remote promotion, learning and even product launches, that have been accelerated by the global pandemic, and how this may effect future practices in the industry.

Indian Firms' Q2 Outlook (Starts 21:05)

India's pharma industry is set to report results for the fiscal second quarter ended 30 September, with performance likely to be impacted in various ways by the coronavirus. Vibha breaks down and pulls out the major expected trends.

Japan Deal-Making (Starts 25:55)

Over the past few months, Japanese companies have been involved in some major transactions, including multi-billion dollar licensing deals and large divestments. Ian looks at how these are significant for the companies involved and indicative of underlying industry trends beyond the pandemic.

Selected Related Content

(Also see "[China Nears COVID Vaccine Race 'Victory': CNBG](#)" - Scrip, 9 Oct, 2020.)

(Also see "[Korea Gains Speed In Race For NASH Therapies](#)" - Scrip, 3 Sep, 2020.)

(Also see "[COVID-19 and What Doctors Expect From Pharma In India](#)" - Scrip, 1 Jun, 2020.)

(Also see "[Despite Imminent Etanercept Launch, Lupin Cuts FY21 Forecast](#)" - Scrip, 11 Aug, 2020.)

(Also see "[Oncology Deal-Making The Daiichi Way](#)" - Scrip, 27 Jul, 2020.)

(These and other podcasts are also available on Apple Podcasts under the Informa Pharma Intelligence channel and via the Alexa app and Alexa smart speakers. Just set up Informa Pharma Intelligence as a skill and then ask "Alexa - open Informa Pharma Intelligence podcasts".)